End-of-day quote
Pakistan S.E.
06:00:00 2024-06-27 pm EDT
|
5-day change
|
1st Jan Change
|
117.1
PKR
|
+0.19%
|
|
-0.21%
|
-16.26%
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
3,425
|
2,337
|
4,090
|
3,630
|
2,942
|
876
|
Enterprise Value (EV)
1 |
4,332
|
3,467
|
5,082
|
3,990
|
3,389
|
1,813
|
P/E ratio
|
52.4
x
|
-13.3
x
|
44.9
x
|
9.4
x
|
12.7
x
|
-122
x
|
Yield
|
0.42%
|
-
|
-
|
0.5%
|
0.62%
|
2.07%
|
Capitalization / Revenue
|
1.83
x
|
1.24
x
|
1.84
x
|
1.43
x
|
1.03
x
|
0.29
x
|
EV / Revenue
|
2.32
x
|
1.84
x
|
2.28
x
|
1.57
x
|
1.19
x
|
0.6
x
|
EV / EBITDA
|
12.4
x
|
23.2
x
|
16.3
x
|
7.7
x
|
6.39
x
|
6.22
x
|
EV / FCF
|
79.2
x
|
255
x
|
29
x
|
9.29
x
|
-81.3
x
|
-5.09
x
|
FCF Yield
|
1.26%
|
0.39%
|
3.45%
|
10.8%
|
-1.23%
|
-19.6%
|
Price to Book
|
16.9
x
|
99.6
x
|
35
x
|
7.25
x
|
4.13
x
|
1.26
x
|
Nbr of stocks (in thousands)
|
12,100
|
12,100
|
12,100
|
12,100
|
12,100
|
12,100
|
Reference price
2 |
283.0
|
193.1
|
338.0
|
300.0
|
243.1
|
72.40
|
Announcement Date
|
10/3/18
|
9/27/19
|
9/10/20
|
9/6/21
|
10/3/22
|
9/14/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,869
|
1,885
|
2,227
|
2,546
|
2,852
|
3,035
|
EBITDA
1 |
350
|
149.7
|
312.6
|
518.1
|
530.4
|
291.4
|
EBIT
1 |
257.1
|
64.07
|
225.9
|
429.7
|
438.5
|
206
|
Operating Margin
|
13.76%
|
3.4%
|
10.15%
|
16.87%
|
15.38%
|
6.79%
|
Earnings before Tax (EBT)
1 |
138
|
-193.7
|
107.6
|
469.5
|
364.6
|
-28.35
|
Net income
1 |
65.31
|
-175.3
|
91.07
|
386.3
|
231.8
|
-7.207
|
Net margin
|
3.49%
|
-9.3%
|
4.09%
|
15.17%
|
8.13%
|
-0.24%
|
EPS
2 |
5.397
|
-14.49
|
7.526
|
31.93
|
19.16
|
-0.5956
|
Free Cash Flow
1 |
54.72
|
13.58
|
175.4
|
429.4
|
-41.67
|
-356.2
|
FCF margin
|
2.93%
|
0.72%
|
7.87%
|
16.86%
|
-1.46%
|
-11.74%
|
FCF Conversion (EBITDA)
|
15.63%
|
9.08%
|
56.09%
|
82.87%
|
-
|
-
|
FCF Conversion (Net income)
|
83.79%
|
-
|
192.56%
|
111.14%
|
-
|
-
|
Dividend per Share
2 |
1.200
|
-
|
-
|
1.500
|
1.500
|
1.500
|
Announcement Date
|
10/3/18
|
9/27/19
|
9/10/20
|
9/6/21
|
10/3/22
|
9/14/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
907
|
1,130
|
992
|
360
|
447
|
937
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.59
x
|
7.553
x
|
3.174
x
|
0.6958
x
|
0.8433
x
|
3.215
x
|
Free Cash Flow
1 |
54.7
|
13.6
|
175
|
429
|
-41.7
|
-356
|
ROE (net income / shareholders' equity)
|
38.3%
|
-155%
|
130%
|
125%
|
38.2%
|
-1.02%
|
ROA (Net income/ Total Assets)
|
10.6%
|
2.57%
|
8.8%
|
17%
|
16.5%
|
6.23%
|
Assets
1 |
617.6
|
-6,819
|
1,035
|
2,277
|
1,409
|
-115.7
|
Book Value Per Share
2 |
16.80
|
1.940
|
9.650
|
41.40
|
58.90
|
57.60
|
Cash Flow per Share
2 |
1.520
|
0.9100
|
1.890
|
3.680
|
4.400
|
0.4800
|
Capex
1 |
48.1
|
27.4
|
50.7
|
65.8
|
61.7
|
247
|
Capex / Sales
|
2.57%
|
1.46%
|
2.28%
|
2.59%
|
2.16%
|
8.15%
|
Announcement Date
|
10/3/18
|
9/27/19
|
9/10/20
|
9/6/21
|
10/3/22
|
9/14/23
|
|
1st Jan change
|
Capi.
|
---|
| -16.26% | 5.09M | | +20.76% | 43.77B | | +28.00% | 22.83B | | +20.25% | 15.56B | | +18.82% | 14.34B | | +55.83% | 12.96B | | -0.05% | 6.79B | | -12.70% | 6.41B | | -8.87% | 5.73B | | +14.65% | 5.69B |
Generic Pharmaceuticals
|